ArticleNature medicine2023
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Open access · hybridAbstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
24.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Serial cycle threshold to assess the infectious potential of SARS-CoV-2: A systematic review.Epidemiology and infection · 2026Pooled it
- Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients.Nature communications · 2024Trial
- Safety, Pharmacokinetics, and Predicted Neutralizing Activity of the SARS-CoV-2 Monoclonal Antibody Sipavibart: Results from Little DIPPER and the SUPERNOVA Substudy.Infectious diseases and therapy · 2026Article
- Pre-vaccine sentinel antibodies predict blunted vaccine responses.Cell press blue · 2026Article
- Factors associated with severe COVID-19 in immunocompromised subgroups in England from 2020 to 2024: an OpenSAFELY cohort study.EBioMedicine · 2026Article
- The impact of ethnicity on longitudinal humoral and cellular immune responses to SARS-CoV-2 booster vaccination.Scientific reports · 2026Article
- Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.Blood advances · 2026Article
- Article
- Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.Nature communications · 2026Article
- Long-term kinetics of anti-RBD IgG antibodies 16 months after COVID-19 vaccination in Morocco: a longitudinal cohort study.Scientific reports · 2026Article
- Understanding the Psychological Impacts of Shielding From COVID-19 for Immunocompromised Individuals.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Palmitoylated COX-2Journal of advanced research · 2026Article
- Systemic inflammatory indices and 28-day mortality in severe pneumonia: a retrospective single-center exploratory study.Frontiers in medicine · 2026Article
- Impact of COVID-19 on Recipients of Solid Organ Transplants: A Cohort Study of In-Hospital Outcomes From the Canadian Organ Replacement Register.Canadian journal of kidney health and disease · 2026Article
- The Impact of the COVID-19 Pandemic on an Immunocompromised Patient with Allogeneic Haematopoietic Stem Cell Transplant: A Dual Perspective from Patient and Physician Standpoints.Oncology and therapy · 2025Article
- Limited vaccine-induced CD8+ T cell immunity in HIV-infected immunological nonresponders.JCI insight · 2025Article
- TF-343 Recovered Cyclophosphamide-Induced Compromised Immune Status in a Mouse Model.Journal of microbiology and biotechnology · 2025Article
- Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination.NPJ vaccines · 2025Article
- Article
- Nationwide longitudinal analysis of COVID-19 hospitalisation burden in immunocompromised patients.Scientific reports · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors at 20 institutions in 1 country.
Eleanor Barnes *Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-0860-0831
Carl S Goodyear *College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0001-5926-5941
Michelle Willicombe *Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, UK.ORCID http://orcid.org/0000-0002-6404-0584
Charlotte Gaskell *Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, UK.
Stefan SiebertCollege of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0002-1802-7311
Thushan I de SilvaDepartment of Infection, Immunity and Cardiovascular Disease, The Medical School, The University of Sheffield, Sheffield, UK.ORCID http://orcid.org/0000-0002-6498-9212
Sam M MurrayNuffield Department of Medicine, University of Oxford, Oxford, UK.
Daniel ReaCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, UK.
John A SnowdenDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK.ORCID http://orcid.org/0000-0001-6819-3476
Miles CarrollWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Sarah PirrieCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, UK.
Sarah J BowdenCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, UK.
Susanna J DunachieNuffield Department of Medicine, University of Oxford, Oxford, UK.
Alex RichterClinical Immunology Service, University of Birmingham, Edgbaston, Birmingham, UK.
Zixiang LimNuffield Department of Medicine, University of Oxford, Oxford, UK.
Jack SatsangiNuffield Department of Medicine, University of Oxford, Oxford, UK.
Gordon CookNational Institute for Health Research, Leeds MIC, University of Leeds, Leeds, UK.
Ann PopeCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, UK.
Ana HughesCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, UK.
Molly HarrisonCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, UK.
Sean H LimCentre for Cancer Immunology, University of Southampton, Southampton, UK.
Paul MillerBritish Society of Blood and Marrow Transplantation and Cellular Therapy, Guy's Hospital, London, UK.
Paul KlenermanNuffield Department of Medicine, University of Oxford, Oxford, UK.
PITCH consortium
Neil BasuCollege of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Ashley GilmourCollege of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Sophie IrwinNuffield Department of Medicine, University of Oxford, Oxford, UK.
Georgina MeachamNuffield Department of Medicine, University of Oxford, Oxford, UK.
Thomas MarjotNuffield Department of Medicine, University of Oxford, Oxford, UK.
Stavros DimitriadisNuffield Department of Medicine, University of Oxford, Oxford, UK.
Peter KelleherDepartment of Infectious Diseases, Imperial College London, School of Medicine Chelsea and Westminster Hospital, London, UK.ORCID http://orcid.org/0000-0002-4392-5527
Maria PrendeckiCentre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, UK.ORCID http://orcid.org/0000-0001-7048-7457
Candice ClarkeCentre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, UK.
Paige MortimerCentre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, UK.
Stacey McIntyreCentre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, UK.
Rachael SelbyDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK.
Naomi MeardonDepartment of Infection, Immunity and Cardiovascular Disease, The Medical School, The University of Sheffield, Sheffield, UK.
Dung NguyenWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Tom TiptonWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Stephanie LongetWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Stephen LaidlawWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Kim OrchardDepartment of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Georgina IrelandUK Health Security Agency (UKHSA), Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
CONSENSUS
David Thomas *Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, UK.ORCID http://orcid.org/0000-0002-9738-2329
Pamela Kearns *Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, UK.
Amanda Kirkham *Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, UK.
Iain B McInnes *College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK. Iain.McInnes@glasgow.ac.uk.ORCID http://orcid.org/0000-0003-4449-8501
OCTAVE Collaborative Group
University of Oxford · GBUniversity of Glasgow · GBCancer Research UK Clinical Trials Unit · GBCentre for Human Genetics · GBImperial College London · GBUK Health Security Agency · GBCambridge University Hospitals NHS Foundation Trust · GBImperial College Healthcare NHS Trust · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBSt George’s University Hospitals NHS Foundation Trust · GBFreeman Hospital · GBUniversity of Liverpool · GBRoyal Hallamshire Hospital · GBUniversity of Birmingham · GBUniversity of Leeds · GBUniversity of Sheffield · GBChurchill Hospital · GBNational Institute for Health Research · GBNewcastle University · GBSouthampton General Hospital · GB
Funding
Cancer Research UK 27179Cancer Research UK C22436/A25354Department of Health COV19-RECPLASDepartment of Health NIHR300791Medical Research Council MC_PC_20031Medical Research Council MR/W02067X/1Medical Research Council MR/X009297/1Wellcome TrustWellcome Trust 110058/Z/15/Z
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19) vaccines. Overall, 255 of 2,204 (12%) patients failed to develop anti-spike antibodies, with an additional 600 of 2,204 (27%) patients generating low levels (<380 AU ml
Indexed as
COVID-19SARS-CoV-2Antibodies, ViralBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesHumansVaccinationAntibodies, ViralBNT162 VaccineChAdOx1 nCoV-19COVID-19 Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.